190 related articles for article (PubMed ID: 10626935)
1. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
McAllister LD; Doolittle ND; Guastadisegni PE; Kraemer DF; Lacy CA; Crossen JR; Neuwelt EA
Neurosurgery; 2000 Jan; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
[TBL] [Abstract][Full Text] [Related]
2. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
3. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
[TBL] [Abstract][Full Text] [Related]
4. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.
Fliessbach K; Urbach H; Helmstaedter C; Pels H; Glasmacher A; Kraus JA; Klockgether T; Schmidt-Wolf I; Schlegel U
Arch Neurol; 2003 Apr; 60(4):563-8. PubMed ID: 12707070
[TBL] [Abstract][Full Text] [Related]
5. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
6. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study.
Fliessbach K; Helmstaedter C; Urbach H; Althaus A; Pels H; Linnebank M; Juergens A; Glasmacher A; Schmidt-Wolf IG; Klockgether T; Schlegel U
Neurology; 2005 Apr; 64(7):1184-8. PubMed ID: 15824344
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG).
O'Brien PC; Roos DE; Liew KH; Trotter GE; Barton MB; Walker QJ; Poulsen MG; Olver IN
Med J Aust; 1996 Oct; 165(8):424-7. PubMed ID: 8913243
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma.
Juergens A; Pels H; Rogowski S; Fliessbach K; Glasmacher A; Engert A; Reiser M; Diehl V; Vogt-Schaden M; Egerer G; Schackert G; Reichmann H; Kroschinsky F; Bode U; Herrlinger U; Linnebank M; Deckert M; Fimmers R; Schmidt-Wolf IG; Schlegel U
Ann Neurol; 2010 Feb; 67(2):182-9. PubMed ID: 20225195
[TBL] [Abstract][Full Text] [Related]
13. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
14. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Fortin D; Gendron C; Boudrias M; Garant MP
Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
Poortmans PM; Kluin-Nelemans HC; Haaxma-Reiche H; Van't Veer M; Hansen M; Soubeyran P; Taphoorn M; Thomas J; Van den Bent M; Fickers M; Van Imhoff G; Rozewicz C; Teodorovic I; van Glabbeke M;
J Clin Oncol; 2003 Dec; 21(24):4483-8. PubMed ID: 14597741
[TBL] [Abstract][Full Text] [Related]
17. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
O'Brien PC; Roos DE; Pratt G; Liew KH; Barton MB; Poulsen MG; Olver IN; Trotter GE;
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):408-13. PubMed ID: 16198065
[TBL] [Abstract][Full Text] [Related]
18. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
19. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
Hoang-Xuan K; Taillandier L; Chinot O; Soubeyran P; Bogdhan U; Hildebrand J; Frenay M; De Beule N; Delattre JY; Baron B;
J Clin Oncol; 2003 Jul; 21(14):2726-31. PubMed ID: 12860951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
